NorthWest Biotherapeutics Inc (NWBO)

[ou71764]

I added. I still think an early halt (on the first review) is unlikely, but I believe it's more likely than I originally thought.

I am basing this on the idea that if the DMC is on the fence on whether or not to recommend a halt, that the OS numbers will be the deciding factor for them.

I think the percent with tumor shrinkage or not seeing new growth will be high, but I don't think that will be quite enough to get the DMC to call for a halt on the first review. I believe they'd need a little more, and that's where OS comes in.

Nothing new came up. I just saw it differently when I was looking at the prior discussion this morning.

And even if there isn't a halt, there could be one at the 2nd review. And if not there, I still think we'll see approval if the trial runs its full course.